Wall Street analysts expect that Avanos Medical Inc (NYSE:AVNS) will report $0.24 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Avanos Medical’s earnings, with the lowest EPS estimate coming in at $0.22 and the highest estimate coming in at $0.29. Avanos Medical posted earnings per share of $0.73 in the same quarter last year, which indicates a negative year over year growth rate of 67.1%. The company is expected to issue its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that Avanos Medical will report full-year earnings of $1.83 per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of $1.34 per share, with EPS estimates ranging from $1.23 to $1.45. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover Avanos Medical.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Avanos Medical from a “sell” rating to a “hold” rating in a report on Thursday, January 17th. Barclays lowered shares of Avanos Medical from an “equal weight” rating to an “underweight” rating in a report on Friday, January 4th. KeyCorp lowered their target price on shares of Avanos Medical from $68.00 to $67.00 and set an “overweight” rating for the company in a report on Tuesday, December 18th. Finally, TheStreet lowered shares of Avanos Medical from a “b-” rating to a “c” rating in a report on Wednesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. Avanos Medical currently has an average rating of “Hold” and a consensus target price of $67.25.
Shares of Avanos Medical stock traded up $0.53 during trading on Tuesday, hitting $46.54. The stock had a trading volume of 316 shares, compared to its average volume of 341,436. The firm has a market capitalization of $2.12 billion, a PE ratio of 19.80 and a beta of 1.47. The company has a current ratio of 2.78, a quick ratio of 2.32 and a debt-to-equity ratio of 0.19. Avanos Medical has a 12 month low of $38.00 and a 12 month high of $72.96.
In related news, SVP John W. Wesley purchased 1,000 shares of Avanos Medical stock in a transaction that occurred on Monday, November 19th. The shares were bought at an average price of $47.48 per share, with a total value of $47,480.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Joseph Fralin Woody purchased 3,500 shares of Avanos Medical stock in a transaction that occurred on Wednesday, November 28th. The stock was bought at an average cost of $43.35 per share, for a total transaction of $151,725.00. The disclosure for this purchase can be found here. Insiders bought a total of 6,500 shares of company stock valued at $286,685 in the last 90 days. Company insiders own 1.44% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. First Hawaiian Bank purchased a new position in Avanos Medical in the 4th quarter worth about $45,000. Bollard Group LLC purchased a new position in Avanos Medical during the 3rd quarter valued at about $100,000. Rehmann Capital Advisory Group purchased a new position in Avanos Medical during the 3rd quarter valued at about $108,000. Whittier Trust Co. purchased a new position in Avanos Medical during the 3rd quarter valued at about $110,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Avanos Medical during the 2nd quarter valued at about $136,000. 91.07% of the stock is currently owned by institutional investors.
About Avanos Medical
Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
See Also: Stop Order
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.